A Phase 3 interventional study of Rifaximin and Placebo in Non-Constipation Irritable Bowel Syndrome, sponsored by Bausch Health Americas, Inc.. Completed at 88 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-29.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rifaximin in Diarrhea — 1 open to participants now, 2 under way, none of them phase 3. Rifaximin · Diarrhea.
Among the 19 studies testing rifaximin in Diarrhea, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 3, and was the 7th registered.
879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.
Browse Diarrhea studies →1 of the 19 studies testing rifaximin in Diarrhea is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
By country, each count listing its studies:
Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2008.
This study's enrollment of 637 is above the median of 138 across 739 interventional studies indexed under Diarrhea.
Median enrollment 210 across the 19 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
11 studies in Diarrhea by Bausch Health Companies Inc.: 1 open now, 1 under way, none of them phase 3. Of 10 finished, 8 (80%) have results posted.
Among the 11 studies in Diarrhea by Bausch Health Companies Inc., this one is the 3rd largest by enrollment, is one of 2 that started in 2008, is one of 8 in phase 3, and was the 6th registered.
Bausch Health Companies Inc.’s Diarrhea studies by the year they started, since 2004.
1 of the studies testing rifaximin in Diarrhea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285785Bausch Health Americas, Inc.Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea | 2027-04-20 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing rifaximin in Diarrhea, from their registry updates:
Among Bausch Health Companies Inc.’s 11 in Diarrhea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
Drug: Placebo
Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
Drug: Rifaximin
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? \[Yes/No\]"
Time frame: 4 weeks
Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)
The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? \[Yes/No\]."
Time frame: 4 weeks
| Milestone | Placebo | Rifaximin |
|---|---|---|
| Started | 321 | 316 |
| Completed | 302 | 301 |
| Not completed | 19 | 15 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 8 | 6 |
| Withdrew: Lost to follow-up | 6 | 6 |
| Withdrew: Noncompliance | 2 | 1 |
| Withdrew: Subject randomized although ineligible | 1 | 1 |
| Withdrew: Subject had to leave vicinity of site | 0 | 1 |
The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? \[Yes/No\]"
| percentage of responders | Placebo | Rifaximin |
|---|---|---|
| Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6). | 32.2 | 40.6 |
The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? \[Yes/No\]."
| percentage of responders | Placebo | Rifaximin |
|---|---|---|
| Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6) | 31.9 | 41.0 |
Collected over 12 weeks. Adverse events were collected during the 2-week treatment period and during the 10-week follow-up period.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 7/320 (2.2%) | 94/320 (29.4%) |
| Rifaximin | — | 7/315 (2.2%) | 86/315 (27.3%) |
| Event | Placebo | Rifaximin |
|---|---|---|
| Chest painGeneral disorders | 2/320 | 1/315 |
| MeningitisInfections and infestations | 0/320 | 1/315 |
| Atrial fibrillationCardiac disorders | 0/320 | 1/315 |
| Non-cardiac chest painGeneral disorders | 0/320 | 1/315 |
| Intervertebral disc displacementMusculoskeletal and connective tissue disorders | 0/320 | 1/315 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/320 | 1/315 |
| HypoaesthesiaNervous system disorders | 0/320 | 1/315 |
| HypertensionVascular disorders | 0/320 | 1/315 |
| AppendicitisInfections and infestations | 1/320 | 0/315 |
| Metabolic acidosisMetabolism and nutrition disorders | 1/320 | 0/315 |
| Event | Placebo | Rifaximin |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 30/320 | 27/315 |
| HeadacheNervous system disorders | 26/320 | 20/315 |
| NasopharyngitisInfections and infestations | 16/320 | 12/315 |
| DiarrhoeaGastrointestinal disorders | 7/320 | 13/315 |
| Abdominal painGastrointestinal disorders | 11/320 | 10/315 |
| NauseaGastrointestinal disorders | 11/320 | 5/315 |
| SinusitisInfections and infestations | 4/320 | 10/315 |
| BronchitisInfections and infestations | 9/320 | 7/315 |
| ConstipationGastrointestinal disorders | 8/320 | 1/315 |
| Back painMusculoskeletal and connective tissue disorders | 8/320 | 7/315 |
The analysis population was the intent-to-treat population, defined as subjects who received at least 1 dose of study drug. Two randomized subjects (1 in each group) did not receive study drug and were not included in the intent-to-treat population.
| Age, Categorical(Participants) | Placebo | Rifaximin | Total |
|---|---|---|---|
| <=18 years | 1 | 0 | 1 |
| Between 18 and 65 years | 282 | 285 | 567 |
| >=65 years | 37 | 30 | 67 |
| Age, Continuous(years) | Placebo | Rifaximin | Total |
|---|---|---|---|
| Mean | 46.3 ± 14.6 | 45.9 ± 13.9 | 46.1 ± 14.2 |
| Sex: Female, Male(Participants) | Placebo | Rifaximin | Total |
|---|---|---|---|
| Female | 225 | 227 | 452 |
| Male | 95 | 88 | 183 |
| Race (NIH/OMB)(Participants) | Placebo | Rifaximin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 2 | 6 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | 3 |
| Black or African American | 14 | 21 | 35 |
| White | 302 | 282 | 584 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of Jul 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →